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ABSTRACT
Post-mortem toxicology seeks to determine cases in which death is a consequence of
the intake of, or exposure to, acutely toxic compounds, most often drugs or alcohols.
In Finland, 800-900 deaths are caused by fatal poisonings due to drugs or alcohols
annually, ethanol being the most common individual substance responsible. Other
alcohols, mainly methanol and ethylene glycol, cause around ten fatal poisoning
cases each year. Drugs, both medicinal and illicit, cause 400-500 fatal poisonings
annually.  Volatile  and  semivolatile  organic  compounds  are  involved  in  fewer  than
ten fatal poisonings annually. Despite the fact that the majority of fatal poisonings
are caused by relatively few individual compounds, toxicological laboratories must
be capable of  identifying and quantifying a wide range of  possible toxicants.  Small
sample volumes, putrefactive changes, and post-mortem redistribution processes
impose special demands on both the laboratory investigation and the interpretation
of results. The two main objectives of the present thesis are, first, to develop new
analytical laboratory methods for toxic alcohols and drugs and, second, to apply
these methods to post-mortem toxicology cases in order to generate reference data
on lethal concentrations for interpretation purposes. Particular attention is given to
the analysis of metabolites and to assessing the significance of metabolite
concentrations.
Metabolites of toxic substances constitute an interpretive resource that is far
from fully exploited in post-mortem toxicology. The therapeutic, toxic, and lethal
concentrations of alcohols and drugs are usually expressed as the concentration of
the parent compound in blood. Yet the toxicity of methanol and ethylene glycol, for
example, is mainly caused by their toxic metabolites, formic acid and glycolic acid,
respectively. A multitude of therapeutic drugs are transformed to metabolites that
possess pharmacological activity similar to or greater than that of the parent drug.
However, quantification of metabolites may be missed out due to the lack of
appropriate analytical methods or the difficulty in acquiring primary reference
standards for the metabolites.
A method for the quantitative analysis of ethylene glycol, glycolic acid, and
formic acid and for the screening of volatile and hydroxylic organic compounds was
developed, using headspace in-tube extraction–gas chromatography-mass
spectrometry (ITEX-GC-MS). Due to the fairly low prevalence of both toxic alcohols
and volatile organic compounds in fatal poisoning cases, the idea of utilizing the
same ITEX-GC-MS instrumentation as two method variants, methyl-derivatized
and underivatized, offered a cost-effective way of performing these analyses.
In fatal poisonings by methanol or ethylene glycol, the concentration of the
parent alcohol varied significantly, whereas the concentrations of formic acid and
glycolic acid in blood were found to be more uniform. Fatal metabolite threshold
concentrations were established for those poisoning cases that had not received
hospital treatment. Practically no ethanol was detected in these cases as ethanol has
a higher affinity for alcohol dehydrogenase and is eliminated first. In cases involving
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putrefaction, significant post-mortem production of formic acid was detected, and
consequently the concentrations of metabolites should always be interpreted
together with those of the parent alcohols.
A comprehensive method for the quantitative monitoring of basic drugs in blood
samples was developed utilizing ultra-high performance liquid chromatography
coupled  with  two  consecutive  detectors:  diode  array  detector  and  corona  charged
aerosol detector (UHPLC-DAD-CAD). This method enabled simultaneous
identification and quantification of over 150 basic drugs and metabolites in a single
run, utilizing historic one-point calibration. The identification power of the method
was enhanced by using the response ratio of the two detectors as an identification
parameter in addition to retention time and ultraviolet spectrum.
Based on the universal response of CAD, the UHPLC-DAD-CAD method was
evaluated for the quantification of drug metabolites using a secondary calibration
method with the corresponding parent drug as a calibration reference standard.
This approach offers a straightforward way of quantifying metabolites, especially N-
demethylated metabolites, on a routine basis with an uncertainty comparable to
ordinary bioanalysis. This is a clear advantage over mass spectrometry based
methods, which usually suffer from highly varying responses between parent drugs
and metabolites.
The metabolite concentrations of certain toxicologically relevant drugs were
studied  in  post-mortem  blood  samples  by  UHPLC-DAD-CAD  using  the  secondary
calibration method. It was found that the metabolite to parent ratios in post-
mortem blood samples were generally comparable to the standard ratios defined in
clinical therapeutic drug monitoring. With the highest post-mortem parent drug
concentrations, the ratios were below the clinical normal ranges, suggesting acute
ingestion or poisoning. These findings encourage forensic toxicologists to gather
extensive metabolite concentration data and actively to use the metabolite to parent




A post-mortem toxicological investigation is performed together with a forensic
autopsy if there are suspicions, circumstances, or autopsy findings that suggest
substance abuse or poisoning that may have had an influence on the death case. A
post-mortem  toxicological  investigation  should  also  be  performed  in  cases  of
suspected unnatural deaths, such as homicides, traffic accidents, occupational
accidents, and malpractice, when the deceased is a child or a young adult, and when
the cause of death remains unknown at autopsy. Deaths of known drug and alcohol
abusers are often associated with accidental or suicidal overdoses [1]. In Finland, a
forensic pathologist evaluates the significance of the toxicological findings in the
death, occasionally after consulting a forensic toxicologist. Autopsy findings and
laboratory investigations as well as anamnestic and circumstantial evidence help the
forensic pathologist to conclude the cause and manner of death. The causes of death
are coded according to the ICD-10 classification of the World Health Organization
(WHO).  Information  from  death  certificates  is  then  used  in  the  national  cause  of
death database and national mortality statistics. Currently, the medico-legal autopsy
rate and the post-mortem toxicology rate from all deaths in Finland are as high as
17% and 12%, respectively, while the medico-legal autopsy rate in many European
countries is lower.
Annually 800-900 deaths in Finland are caused by fatal poisoning due to
alcohols  or  drugs.  In  2013,  there  were  861  fatal  poisonings  of  which  312  were
alcohol poisonings and 476 poisonings by drugs and medicines. Carbon monoxide
caused 62 poisonings, and 11 poisonings were due to miscellaneous substances such
as hydrogen cyanide and other volatile compounds. Of the alcohol poisonings,
methanol (MeOH) and ethylene glycol (EG) caused seven and four deaths,
respectively [2]. In post-mortem toxicology, the main emphasis has traditionally
been on detecting and quantifying the toxicants in their unchanged form in the
blood, and the cause of death has been determined largely from these
concentrations [3]. Furthermore, published therapeutic and toxic reference
concentrations are mainly for parent compounds in clinical plasma samples [4]. The
importance of metabolites has lately become evident in the interpretation of forensic
cases.  The  toxicity  of  MeOH  and  EG  is  mainly  caused  by  their  acidic  metabolites,
formic acid (FA) and glycolic acid (GA), and many medicinal drugs have metabolites
that possess pharmacological activity similar to the parent drug.
Quantification  of  FA  and  GA  is  useful,  as  the  concentrations  can  be  used  as
criteria for starting hemodialysis [5]. Interestingly, analytical methods for the
simultaneous quantification of both the parent alcohols and their metabolites in
emergency  toxicology  have  not  been  presented  until  very  recently  [6,7].  In
therapeutic drug monitoring (TDM), the importance of metabolite quantification
has been emphasized both for drugs that have pharmacologically active metabolites
and for inactive metabolites to ascertain patients’ compliance and ability to
metabolize drugs [8]. Furthermore, normal ranges of metabolite to parent ratios
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have been published [9], and ratios deviating from these ranges can indicate
problems in drug adherence or altered metabolism caused by genetic variation or
drug-drug interaction.
In post-mortem toxicology, the sample volume is often limited, so there is a
demand for comprehensive screening methods that can be used for simultaneous
quantification of the compounds detected [10]. Gas chromatography-mass
spectrometry  (GC-MS)  has  long  been  a  widely  recognized  technique  in
comprehensive  drug  screening  [11,12].  In  view  of  the  non-volatile  and  hydrophilic
nature of many current drugs, liquid chromatographic (LC) methods, especially
coupled to MS, have become increasingly important [12,13]. MS-based
quantification methods, however, are calibration-intensive and rely on primary
reference standards for each analyte analyzed in the same sequence of runs with the
samples.  Quantification of  drug metabolites is  thus often disregarded,  because the
availability of reference standards is limited and their prices are high.
Non-MS detection in chromatography offers a more stable response with less
calibration work. The emergence of universal detectors, notably the corona charged
aerosol detector (CAD), shows potential for quantification without primary
reference standards. As the CAD response is basically independent of the chemical
structure of the analyte, quantification might be performed using a secondary
calibration standard.
In the absence of post-mortem reference values for potentially toxic substances,
and especially for their metabolites, the reference values obtained from living
subjects are commonly used to interpret post-mortem toxicological results.
However, due to post-mortem redistribution (PMR), the concentrations of drugs
may be significantly different between ante-mortem and post-mortem samples [14].
On the other hand, the metabolite to parent ratios of antidepressants, for example,
have shown to remain constant even when the absolute concentrations are affected
by post-mortem changes [15,16].
These considerations call for improved laboratory methods for the analysis of
metabolites along with the parent toxicants in post-mortem samples, and further,
the routine utilization of these methods in casework to accumulate concentration
data for interpretation purposes.
Review of the Literature
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2. REVIEW OF THE LITERATURE
2.1 Toxic alcohols and drugs
2.1.1 Toxic alcohols and volatile compounds
Toxic  alcohols,  mainly  methanol  (MeOH)  and  ethylene  glycol  (EG),  are  used  in
products such as windshield washing fluids and antifreeze agents available in petrol
stations and stores. They have intoxicating effects similar to those of ethanol, but
their toxicity is much higher. The lethal dose of both MeOH and EG for an adult is
approximately 100 mL, or 1–2 mL/kg for MeOH and 1.4–1.6 mL/kg for EG [17-19].
With MeOH, permanent visual damage may occur with as little as 0.1 mL/kg [20].
Both substances cause fatal poisonings, either accidental when the toxic alcohol is
confused with ethanol or when contaminated ethanol is consumed, or intentional in
cases of suicide or homicide. EG poisonings are usually individual cases, but MeOH
poisonings occur both as individual events and as epidemics [21]. MeOH poisoning
epidemics occur world-wide and are usually related to contaminated beverages sold
as ethanol [22-26]. Simultaneous ingestion of MeOH and EG is rare, and only one
fatal case has been reported so far [27].
The metabolisms of MeOH and EG are illustrated in Fig. 1. MeOH and EG are
metabolized in the liver similarly to ethanol, first by alcohol dehydrogenase (ADH)
to formaldehyde and glycoaldehyde, respectively, and further by aldehyde
dehydrogenase (ALDH) to formic acid (FA) and glycolic acid (GA), respectively
[28,29].  GA  is  further  metabolized  to  glyoxylic  acid  and  oxalic  acid  (OX).  OX
combines with calcium to form the poorly soluble calcium oxalate monohydrate
(COM) and dihydrate crystals that can be detected in urine [30]. In addition,
approximately 20% of EG is excreted unchanged via the kidneys. Even though
formaldehyde and glycoaldehyde are toxic compounds, they have a minor impact in
the toxicity of MeOH and EG as they are rapidly converted to FA and GA.
Glycoaldehyde has not been detected in acute EG poisonings and the glyoxylate
concentrations  have  been  <0.2  mM  [30,31].  Compared  to  other  phases  of  the
metabolism, the conversion of FA to carbon dioxide and conversion of GA to
glyoxylic acid is slow, which causes their accumulation and makes them responsible
for the toxic effects.
FA,  and  especially  OX,  are  present  in  mammals  in  small  amounts  [32-37],
mainly due to degradation of amino acids and external sources like diet. Small
amounts of MeOH are also present in alcoholic beverages, and accumulation of FA
has been detected in the brains of chronic alcohol abusers [38].
Review of the Literature
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Figure 1. Metabolisms of methanol and ethylene glycol. ADH: alcohol dehydrogenase,
ALDH: aldehyde dehydrogenase, GO: glycolate oxidase, FDH: formate dehydrogenase.
After ingestion of MeOH or EG, there is a latent period before symptoms appear,
approximately 12–24 h for MeOH and 6–12 h for EG [21]. Simultaneous ingestion of
ethanol  delays  the  symptoms,  as  ADH’s  affinity  for  ethanol  is  10-20  times  higher
than  for  MeOH  and  some  100  times  higher  than  for  EG,  and  thus  ethanol  is
metabolized first [17,39,40]. The symptoms of MeOH poisoning include visual
disturbances, central nervous system (CNS) depression and metabolic acidosis
[19,20]. These symptoms are mainly caused by FA, which inhibits the mitochondrial
cytochrome oxidase leading to cellular hypoxia [41,42], damages the myelin sheaths
of the optic nerves leading to visual damage [43-46], and causes necrotic damage in
the basal ganglia leading to CNS depression [47].  Metabolic acidosis is also caused
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by FA, both directly and indirectly [48]. FA increases the ratio between reduced and
oxidized nicotinamide adenine dinucleotide (NADH/NAD ratio), forcing the
conversion of pyruvate to lactate [41,49]. Both lactic acid and FA contribute to the
anion gap and acidosis, FA in the early stages of MeOH poisoning, lactic acid in the
later stages.
Symptoms of EG poisoning include CNS depression with seizures,
cardiopulmonary complications, acute renal failure and delayed neurological
sequelae  [50,51].  Like  FA,  GA  increases  the  NADH/NAD  ratio  and  leads  to
increased levels of lactic acid. The metabolic acidosis in EG poisonings is due to the
joint  effect  of  GA,  OX,  and  lactic  acid  [19].  The  renal  outcome  is  caused  by  COM
crystals  that  deposit  in  the  renal  tubules  and  cause  necrotic  cell  death  [30,52,53].
The  CNS  alterations  in  EG  poisonings  are  partly  caused  by  the  acidic  metabolites
and metabolic acidosis, partly by deposition of COM crystals in the cerebral vessels
[19,54].
Diagnosing toxic alcohol intoxication as early as possible is critical in order to
begin  treatment,  but  it  may  be  challenging  as  the  early  stages  of  MeOH  and  EG
intoxications present the same kind of symptoms as intoxication with ethanol [55].
Furthermore, the infrared breath alcohol analyzers used to estimate blood ethanol
concentrations can falsely report MeOH as ethanol even in cases where no ethanol
has been consumed [56]. This can lead to delayed diagnosis or misdiagnosis and
adverse  outcome  or  even  death.  The  gold  standard  for  diagnosis  is  direct
measurement of MeOH or EG in blood or urine samples with gas chromatographic
(GC) methods [17,55,57]. As GC instrumentation is only available in specialized
laboratories and in major hospital laboratories, enzymatic methods have been
developed  for  MeOH  [58],  FA  [59]  EG  [60,61]  and  GA  [62].  These  methods,
however, suffer from false-positive results caused by less toxic alcohols like ethanol
[63],  propylene  glycol,  and  endogenous  compounds  [64],  and  usually  require
confirmation analysis with chromatographic methods. Other diagnostic tools
include measurement of the osmolal gap, anion gap and acidosis [55,57,65].
However,  these  indirect  tests  are  unspecific,  and  abnormal  results  can  be  due  to
causes other than ingestion of the toxic alcohols. Their value has been questioned,
especially with EG poisonings [66]. If EG intoxication is suspected, urine samples
can be screened for calcium oxalate crystals. This test can also produce both false-
positive and false-negative results, as calcium oxalate crystals are not always present
in intoxication cases [55,67], while OX from dietary sources can cause formation of
crystals [35,55].
Treatment of toxic alcohol poisonings has two important goals: to inhibit the
metabolism of MeOH or EG using either ethanol or fomepizole, and to remove toxic
metabolites by hemodialysis [28,29,48,68-70]. With MeOH poisonings, the
treatment  can  also  include  enhancement  of  FA  metabolism  with  folic  acid.
Measurement of the serum concentration of FA or GA is recommended as an aid to
evaluating whether hemodialysis should be started [5,26,71-73].
Despite the generally well known fact that toxicity of MeOH and EG is directly
correlated with the FA or GA concentration in blood [28,72,74], many laboratories
still screen only for the parent alcohols, and clinical criteria for initiating or
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terminating hemodialysis are based on the concentration of MeOH or EG. Recently,
chromatographic methods utilizing GC with flame ionization detection (FID) and
GC  coupled  with  mass  spectrometry  (GC-MS)  have  been  presented  for  fast  and
efficient quantitative screening of EG, GA and 1,2-propylene glycol [6,7]. These
methods are suitable for emergency toxicology, as the turnaround time is about 30
minutes and no specialized equipment is required.  A combination of quick
colorimetric enzymatic tests that can differentiate between ethanol, MeOH, EG and
diethylene glycol has been presented [75]. This method utilizes saliva samples and
can be performed outside clinical laboratories. In addition, a bedside test for FA was
recently presented [73].
A few papers have reported the concentrations of MeOH, EG, and their acidic
metabolites in post-mortem blood samples [76-79], as well as the distribution of FA
in fatal MeOH poisoning [80]. Plasma FA concentrations in healthy subjects have
also been reported [32-34]. However, in these previous studies the number of cases
has  been  fairly  low.  In  particular,  post-mortem  reference  concentrations  of  FA  in
blood or urinary concentrations of EG and GA in fatal poisonings have not been
available.
Volatile organic compounds (VOC) are a group of miscellaneous chemically
divergent compounds, including aliphatic and aromatic hydrocarbons, oxygenated
compounds such as alcohols, ethers, nitrites, and halogenated compounds like
inhalation anesthetics. Because of their low price and wide availability they are
abused to achieve euphoria and intoxication [81]. Even though the prevalence in
VOC  abuse  has  decreased  in  recent  decades  [82,83],  these  compounds  still  cause
fatalities, especially among young people [81]. VOC are readily absorbed via the
lungs, and due to the extensive capillary surface area in the lungs the peak
concentration in blood is reached rapidly. Due to their generally high lipophilic
properties, VOC are distributed to tissues with high lipid content, such as the CNS,
liver  and  kidneys.  Most  deaths  associated  with  VOC  abuse  are  caused  by  direct
toxicity of the compounds inhaled [84], and the most common cause of mortality is
acute cardiac toxicity [83]. For this reason, the main attention in post-mortem
toxicology  is  given  to  the  parent  compounds  detected  in  blood  as  they  provide  a
direct link to toxicity [81]. If there is a need to evaluate recent exposure or
continuous environmental or occupational exposure, screening urine samples for
the metabolites of VOC can be used [85,86].
When  interpreting  the  results  of  VOC  analysis,  care  is  needed  as  volatile
compounds can easily evaporate if the sample containers are not properly closed.
Furthermore, VOC are formed as a consequence of post-mortem changes from
degrading tissues. Putrefaction is a complicated process that is greatly affected by
the circumstances during the post-mortem period, such as humidity, temperature
and microorganisms [87,88]. There are studies concerning the VOC forming during
putrefaction [89-93], but these reports mainly focus on the compounds released
from decomposed cadavers or carcasses, not compounds detected in blood.
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2.1.2 Medicinal drugs and their metabolites
In many countries, illicit and licit drugs constitute the largest portion of fatal
poisonings. In Finland, the majority of fatal drug poisonings are caused by
medicinal drugs [2]. Table 1 lists the 25 most prevalent single drugs as the principal
finding in fatal poisonings in 2013 along with the number of fatal poisonings caused
by these drugs. Interestingly, the majority of these drugs are therapeutic substances
that generally originate from treatment. Buprenorphine involves a considerable
amount  of  smuggling,  and  the  amphetamines  group  contains  mainly  illicit  drugs.
Approximately two-thirds of these fatal poisonings were caused by concomitant use
of one or more drugs and/or alcohol. Opioids were found in 30–40% of all fatal drug
poisoning cases.
Table 1. The 25 most prevalent single drugs as principle finding in fatal poisonings in
Finland in 2013 with number of cases in parenthesis [2].
Opioids Antidepressants Sedatives Antipsychotics Miscellaneous
Buprenorphine
(50)
Amitriptyline (22) Pregabalin (26) Quetiapine (21) Paracetamol (17)
Tramadol (40) Venlafaxine (17) Temazepam (13) Levomepromazine
(15)
Insulins (17)




Oxycodone (22) Doxepin (9) Alprazolam (10) Olanzapine (8) Amlodipine (9)
Methadone (12) Clozapine (8) Metformin (8)
Fentanyl (11) Propranolol (7)
* Includes all amphetamine-like stimulants
Therapeutic concentrations of drugs are conventionally presented as the
concentration of parent drug in a serum or plasma sample at the steady state, and
extensive lists of therapeutic and toxic plasma concentrations are available [4,94].
However, many medicinal drugs, such as antidepressants, antipsychotics, and
opioids, have pharmacologically active metabolites that possess pharmacological
activity similar to the parent drug. There is a recommendation within therapeutic
drug monitoring (TDM) to use the combined concentrations of the parent drug and
the metabolite for certain drugs with active metabolites [8,9]. These pairs include
for example amitriptyline and nortriptyline, clomipramine and norclomipramine,
doxepin and nordoxepin, risperidone and 9-hydroxyrisperidone, and venlafaxine
and O-desmethylvenlafaxine. Use of the combined concentration has, however, been
criticized [95], as the affinity for target protein between parent drugs and metabolite
can be significantly different. For example, amitriptyline and nortriptyline have
opposite affinities for serotonin and norepinephrine transporters, which
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complicates the assessment of their activity [96]. Doxepin acts as an antihistamine
and  sedative,  whereas  nordoxepin  has  effects  similar  to  those  of  tricyclic
antidepressants [96].
In addition to quantifying the active metabolites, measurement of the
concentrations of  less active metabolites is  also recommended in TDM in order to
gain information on the patient’s compliance and ability to metabolize drugs. To aid
the interpretation of metabolite concentrations, ranges of normal metabolite to
parent ratios for some antidepressants and antipsychotics have been suggested [9].
Deviation from these ranges can indicate altered metabolism due to altered liver
function, polymorphism on the liver cytochrome P450 (CYP) enzymes, or drug-drug
interactions. In particular, changes in CYP2D6 and CYP2C19 affect the metabolism
of several drugs with pharmacologically active metabolites [97].
In the past, the therapeutic and toxic ranges defined with living subjects have
also been applied in post-mortem toxicology due to the lack of post-mortem
reference values. However, these clinical reference concentrations should be applied
with caution, as post-mortem redistribution (PMR) can significantly alter the drug
concentrations in blood samples taken several days after death [98-103].
Particularly in the case of those lipophilic drugs with a high volume of distribution
(Vd), the concentrations measured in post-mortem blood samples can be
significantly higher, even when there is no reason to suspect overdose [99,101]. For
other drugs, such as some benzodiazepines and cocaine, the concentration in post-
mortem  blood  can  be  lowered  by  bacterial  metabolism  after  death  [104,105]  or
instability of the compound in the biological matrix [106]. Furthermore, water-
soluble drugs and drugs with high protein binding and blood to plasma ratio below
unity, such as some anti-epileptics, have been shown to possess lower post-mortem
concentrations [107,108].
Currently there are a few compilations of post-mortem blood drug reference
concentrations  available,  but  attention  has  mainly  been  given  to  the  parent  drugs
and data on metabolite concentrations is scarce [108-111]. A positive exception is the
article by Reis et al. [16] which reports drug and metabolite concentrations and
metabolite to parent ratios for 15 antidepressants divided into groups as follows:
cases of fatal poisoning by a single drug, cases of fatal poisoning where other drugs
are also involved, cases with other causes of death, and clinical TDM cases. Other
available data on post-mortem concentrations of drug metabolites consists mainly
of case studies including individual cases or case series [112-115] or studies focusing
on the genotype’s effect on the parent and metabolite concentrations [116-122].
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2.2 Analytical laboratory methods
2.2.1 Analysis of hydroxylic and volatile compounds
Ethanol is the most commonly analyzed substance in both clinical and forensic
toxicology, and several methods for ethanol determination are available. In clinical
settings methods based on enzymatic oxidation, mainly ADH, are used [123]. ADH
oxidizes ethanol to acetaldehyde using the coenzyme NAD+, which at the same time
is reduced to NADH. After reduction, NADH is measured spectrophotometrically.
Enzymatic methods are fast, sensitive, and simple to use and generally meet all
analytical requirements except specificity [124]. However, as there is a need to
distinguish ethanol from other alcohols and volatile compounds, chromatographic
methods are considered superior in alcohol analysis.
Using chromatographic methods enables the detection and quantification of
volatile alcohols such as MeOH and isopropyl alcohol, and volatile compounds used
as denaturation agents, such as acetone and methyl ethyl ketone, simultaneously
with ethanol. The most widely used chromatographic method for alcohol analysis in
toxicology laboratories worldwide is GC-FID with static headspace sampling [125].
In headspace-GC-FID analysis the sample is diluted with an aqueous solution of the
internal standard, usually n-propanol or t-butanol, and heated in an air-tight glass
vial.  A sample of the gaseous phase is then injected into the GC and analyzed under
isothermal conditions with a run time of a few minutes. The main advantages of
headspace-GC-FID are its ease of automation, sensitivity, accuracy, and specificity,
especially when two columns with different polarities are used [126]. The precision
and accuracy of headspace-GC-FID methods have proved to be very good, generally
the coefficients of variation are 3–5% [127-129]. Furthermore, headspace sampling
has been shown to extend column life and prevent injector contamination, as the
gaseous phase contains fewer components than the biological matrix [125,130]. GC-
FID methods with direct injection [131-133] as well as headspace-solid phase
microextraction (SPME) [134,135] have been presented with the aims of reducing
the sample volume required and increasing the sensitivity of alcohol analysis. The
accuracy  of  the  SPME  method,  however,  has  proved  to  be  poorer  than  that  of  the
static headspace method [136]. GC-MS methods designed to achieve more
unequivocal identification of other volatile compounds simultaneously with ethanol
quantification have been published [126,137,138].  However,  these methods are not
practical in routine alcohol analysis because of their much longer turnaround time.
Because  of  its  high  boiling  point,  EG  cannot  be  determined  as  such  with
headspace-GC methods, and consequently it is seldom included in routine forensic
alcohol analysis. A few chromatographic methods for simultaneous determination of
volatile  alcohols  and  EG  have  been  published,  but  without  including  FA  and  GA
[139-141]. These methods utilize direct injection into the GC-FID after
deproteinization by ultrafiltration or protein precipitation with acetonitrile.
Traditionally EG has been derivatized with phenylboronic acid to form its
phenylboronate ester followed by GC-FID analysis [142-144]. This method,
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however, does not enable the determination of GA. Adding isobutyl chloroformate
as a second derivatizing agent enables the determination of 1,2-propylene glycol and
GA along with EG by either GC-FID [6] or GC-MS [7] using direct injection. Using
silylation [145-147] or derivatization with heptafluorobutyric acid [148] enables
simultaneous  determination  of  GA  by  GC-FID  [145]  or  GC-MS  [146-148]  using
direct injection.  FA is usually determined as a methyl formate ester following
methylation with MeOH in sulfuric acid using headspace-GC-FID [77,78,149]. No
headspace methods for the analysis of EG and GA have been published prior to the
present thesis.
The diversity of VOC poses a challenge to toxicological analysis. Most published
methods  focus  on  identification  or  quantification  of  a  group  of  chemically  similar
compounds such as lighter gas components [150], aromatic hydrocarbons [151-153],
petroleum  products  [154],  inhaled  solvents  [155],  and  propellant  gases  used  in
different aerosol products [156]. Due to their highly volatile nature, analysis of VOC
has traditionally been performed with headspace-GC coupled with either FID
[155,157-159], MS [137,138,150] or Fourier transform infrared spectroscopy (FTIR)
[160]. In addition to static headspace methods, dynamic headspace methods such as
headspace-SPME [152,161] and purge-and-trap sampling [151,160,162] have also
been presented. The chromatographic separation can be performed with commonly
used capillary GC columns, but using a column with a greater film thickness results
in  better  separation  of  VOC  [81].  Even  though  FID  has  good  sensitivity  for
hydrocarbons, identification of VOC is simplified when spectral detectors like MS or
FTIR  are  used.  For  low  molecular  weight  compounds,  the  MS  spectra  are  less
specific  and  FTIR  can  provide  more  information  [81].  The  sensitivity  of  FTIR,
however, is lower than that of MS, and most current methods utilize MS detection
[137,150,152,156].
2.2.2 In-tube extraction (ITEX)
In-tube extraction (ITEX) is a dynamic headspace microextraction technique that
has  been  commercially  available  since  2006  [163].  As  with  SPME,  the  equipment
consists of a gastight syringe, a needle filled with sorbent material and an external
heater. The extraction procedure has four stages: sample conditioning, extraction,
injection by thermal desorption, and trap cleaning. Unlike with SPME, the traps can
be used multiple times and sampling is fully automated. The extraction procedure is
illustrated in Fig. 2. In the first phase, the sample is heated and mixed, resulting in
equilibrium of the analytes in the sample and the gas phase above the sample. Once
equilibrium has been reached, the gas phase is aspirated through the sorbent-
packed needle several times, enriching the analytes in the sorbent and resulting in a
new equilibrium between the sample and the gas phase after each extraction stroke.
After the extraction, the sorbent is flash heated and the analytes are injected into the
GC injector by thermal desorption. In the cleaning phase, the trap is flushed with
inert gas to prevent carryover.
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Figure 2. Principle of in-tube extraction (ITEX). A: Sample is heated and mixed until
equilibrium is reached. B: Gas phase (headspace) is repeatedly pumped through a heated
needle containing Tenax trap. C: Trap is flash heated and analytes are desorbed into GC
injector.
Several factors affect the extraction efficiency, the most notable being the
sorbent  material,  the  temperatures  of  the  sorbent  and  the  sample,  the  number  of
extraction strokes, and the extraction speed [164,165]. Each extraction stroke
increases the sensitivity, and for most compounds maximum sensitivity cannot be
reached  even  after  50  strokes  [165].  As  each  cycle  increases  the  analysis  time,  a
compromise has to be reached between sensitivity and throughput of the method.
ITEX-GC-MS has been utilized in the analysis of volatile organic hydrocarbons
from aqueous samples [165,166], volatile aroma compounds in alcoholic and non-
alcoholic beverages [167-170] and plants [163], aliphatic hydrocarbons in petroleum
source rocks [171], and for metabolic profiling of oxidized lipid-derived volatiles in
blood  [172].  No  ITEX  applications  have  been  published  for  the  analysis  of  toxic
alcohols and their metabolites within clinical or post-mortem toxicology prior to the
present thesis.
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2.2.3 Liquid chromatography-diode array detection (LC-DAD)
Electron ionization (EI) GC-MS in the full scan mode is a standard technique for
comprehensive drug screening due to its sensitivity and specificity and the excellent
reproducibility of mass spectra, which enables the use of large spectral libraries
[173]. In the selected ion monitoring (SIM) mode, the technique has established its
position in the confirmation analysis of target drugs. However, only thermally stable
and sufficiently volatile drugs can be detected in their native form, while others
require derivatization [174,175]. Derivatization can lead to formation of artifacts
from drugs or metabolites, complicating identification. The hydrophilic and
nonvolatile nature of many drugs makes reversed-phase liquid chromatography
(RPLC) a suitable method for toxicological analysis as no derivatization is needed
[176,177]. Furthermore, of the toxicologically interesting compounds, some 90%
have significant ultraviolet (UV) absorption, making DAD a useful general detector
[173,175,178].  The  high  long-term  stability  of  DAD  detection  compared  to  MS
techniques is a clear advantage and enables quantification using historic calibration
[173,179].
In RPLC, chromatographic separation of analytes is performed on a nonpolar
stationary phase with an aqueous, moderately polar mobile phase [177]. DAD
detection is based on UV absorption caused by the analyte chromophores, generally
the  conjugated  π-electrons  and  the  free  electron  pairs  of  heteroatoms  [173].  Two
molecules sharing the same absorption system can usually be distinguished because
of the electronic or steric effects caused by other parts of the molecule. If a molecule
has more than one chromophore, the UV spectrum is approximately the sum of the
spectra caused by each chromophore [173].
The applicability of LC-DAD methods in forensic toxicology casework was
presented already in the 1990s [180]. The evolution of software and detectors has
enabled the use of LC-DAD in routine analysis [173,181-185]. Advances in detector
technology  and  software  made  it  possible  to  collect  and  process  the  whole  UV
spectrum, which enables the monitoring of peak purity, detecting co-eluting peaks
[186,187], and comparison with spectral libraries [173]. In similarity comparison,
the two spectra are described as vectors in an n-dimensional space, where n is the
number  of  absorbance-wavelength  pairs.  The  length  of  the  vector  is  only
proportional to the concentration of the compound. Similarity between two spectra
is expressed as the angle between the two vectors, θ, or as cosine θ, called similarity
index  (SI)  [173,188,189].  The  smaller  the  θ,  or  the  closer  to  1  the  SI  is,  the  more
similar the spectra are. SI>0.9990 (or θ<2.56) is considered positive identification.
Between SI=0.9900 and SI=0.9990 (2.6<θ<8.1), the spectra are very similar, but
differences may occur [173].
Since the introduction of LC coupled to tandem mass spectrometry (LC-
MS/MS), LC-DAD methods have been held in lower esteem, as the UV spectra
display  only  a  limited  number  of  maxima  and  minima,  and  there  is  no  simple
correlation to the chemical structure [178]. However, the identification power of LC-
DAD  was  proved  to  be  comparable  to  GC-MS  as  long  ago  as  the  1990s,  when
spectral data was used in conjunction with retention indices [181]. In the analysis of
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61 toxicologically relevant drugs, an accuracy rate of 96.7% was achieved when both
the UV spectra and relative retention times were used for identification [190]. These
results are comparable to those obtained with conventional GC-MS methods. In a
study of over 2,500 drugs, 84.2% of analytes were distinguishable from each other
when UV spectra and relative retention time were used [178].
However, the limitations of LC-DAD methods include lower sensitivity
compared to MS-based methods [185] and problems in detecting compounds with
little or no UV absorption [176]. Furthermore, the shape of the UV spectrum is
dependent on the mobile phase pH, which makes the use of commercial UV spectral
libraries difficult [178]. Spectral libraries have been made available, but if these are
to be used the analytes should be measured under similar conditions, i.e. with the
same kind of aqueous buffer at the same pH as that used to build the library [173].
2.2.4 Ultra-high performance liquid chromatography (UHPLC)
The weaknesses of high performance liquid chromatography (HPLC) were the
moderately low separation efficiency and long analysis times, which limit its use in
the separation of complex mixtures [191]. It was shown long ago that substantially
better separation efficiencies and shorter analysis times can be achieved with
smaller stationary phase particles [192]. However, decreasing the column particle
size  increased  the  backpressure  above  the  allowed  HPLC  pressure  limit  of  usually
6 000 psi, unless the column length was reduced at the same time [193]. Increasing
the  column  temperature  lowers  the  viscosity  of  the  mobile  phase  and  hence  the
backpressure, but, especially in the analysis of pharmaceutical compounds, the
column temperature is typically limited to < 60°C to avoid on-column degradation
of analytes [193]. For this reason, 250 mm × 4.6 mm i.d. columns packed with 5 μm
particles were mostly used in HPLC separations. The first commercial UHPLC
instrument with a system pressure limit of 15 000 psi was introduced in 2004, and
after improvements in detector technology, applications utilizing UHPLC have
increased [194]. The UHPLC columns are typically 100–150 mm long with an i.d. of
2.1  mm,  packed  with  pH-stable,  sub-2  μm  particles  [191].  The  introduction  of
UHPLC  has  considerably  improved  the  performance  of  LC  systems  in  terms  of
resolution, speed and reproducibility [177]. However, LC-MS systems rarely utilize
the full power of UHPLC due to restrictions in the mobile phase composition.
2.2.5 Corona charged aerosol detector (CAD)
The idea of universal aerosol detection for LC was first introduced in 2002 [195] and
the detector was made commercially available in 2004. The operating principle of
CAD is illustrated in Fig. 3. The principle is similar to that of atmospheric pressure
chemical ionization (APCI). The LC mobile phase is first nebulized to droplets using
a nitrogen flow, and the resulting aerosol is transported through a drift tube where
the remaining solvent and volatile components are evaporated off. Analyte particles
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are then collided with a stream of positively charged nitrogen and the charge is
transferred to the particles. The charged particles are directed to the collector where
the charge is measured using a sensitive electrometer [196,197]. The response of the
detector  is  independent  of  the  chemical  or  physical  properties  of  the  analyte  and
directly proportional to the weight of the analyte present. However, as with MS and
evaporative light scattering detection (ELSD), the composition of the mobile phase
has  an  effect  on  the  response  [198].  The  peak  areas  have  been  shown  to  increase
nearly five-fold when the proportion of acetonitrile was increased from 10% to 90%.
This effect can be corrected using an inverse gradient. The response of CAD is not
absolutely linear, but over a range of two orders of magnitude a linear response has
been achieved [197,199].
Figure 3. Operating principle of the corona charged aerosol detector (CAD). Mobile phase
from LC is nebulized into droplets in the nebulizer (1) and large droplets are removed. The
droplets are dried into particles in the drying tube (2). In the charge transfer chamber (3) the
particles are collided with nitrogen gas charged using a corona discharge needle (4) and the
charge is transferred to the particles. Charged particles are transferred to a collector (5)
where charge is measured with an electrometer.
Compared with other universal detectors, CAD has several advantages. Unlike
chemiluminescent nitrogen detector (CLND) and UV detectors, it is truly universal
for non-volatile compounds. Analytes lacking chromophores and nitrogen can also
be detected. Depending on the analyte structure, it has also been shown to be more
sensitive than UV or ELSD [196,197,200]. In addition, the linearity of CAD has
proven to be better than that of ELSD [196].
CAD has been used in the analysis of pharmaceutical products, both for
detecting impurities [201-206] and for quantifying active pharmaceutical
ingredients  [197,200,207-210].  The  detector  has  also  been  used  in  the  analysis  of
antibiotics in biological samples [211], pollutants in water [212] and food additives
in food supplies and beverages [213-215]. No CAD applications have been published
for the analysis of drugs and metabolites within clinical or post-mortem toxicology
prior to the present thesis.
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2.3 Quantification of drug metabolites without reference
standards
There is a constant need for the quantitative analysis of drug metabolites in many
disciplines, including drug development and toxicology. However, the availability of
synthetic  primary  reference  standards  is  limited  or  their  price  can  be  high.  To
overcome this challenge, several approaches have been presented. In drug discovery
and development as well as in preclinical research, radiolabeled drugs and
radiometric detection have traditionally been used for the evaluation of metabolite
concentrations [216,217]. Other techniques include utilization of modified LC-MS
methods, nuclear magnetic resonance detectors (NMR), and universal detectors.
 LC-MS methods are widely used in drug analysis because of their selectivity,
sensitivity, and speed. However, the response of LC-MS with electrospray ionization
(ESI) to analytes is non-uniform because of the different ionization efficiencies
caused by different chemical structures and LC gradients [218-220], and
consequently calibration with the primary reference standard is necessitated in
every sequence of runs [221]. Several attempts to equalize the MS responses have
been presented, for example by using a parallel detector that provides equimolar
responses [218,222,223], or by using a calibration factor obtained with a different
ionization technique, such as nanospray ionization (NSI) [219,224-228] or captive
spray ionization (CSI) [229,230].
Semi-equimolar responses for several structurally distinct drugs and their
metabolites have been achieved when a very low flow rate LC-NSI-MS technique
was used [224]. Even more uniform responses were achieved when an inverse
gradient was used with LC-NSI-MS [226]. LC-NSI-MS techniques have not,
however, gained wide use because of the difficulties associated with their
maintenance, operation, and reproducibility [229]. To overcome these issues,
commercially available LC-CSI-MS has been tested in the quantification of drug
metabolites [229,230]. The suitability of LC-CSI-MS for quantification without
primary reference standards has remained controversial and the technique has not
been widely adopted. While good results have been reported [229], others have
reported statistically significant differences in the calibration curves of drugs and
their metabolites [230].
Correcting  the  LC-ESI-MS  responses  with  universal  detectors  such  as  CLND
[218]  and  UV  detectors  has  also  been  tested  [222,223].   When  the  LC-ESI-MS
response was corrected with a calibration factor gained from CLND, the quantitative
results for benzodiazepines using a secondary calibration were comparable to those
obtained with conventional calibration [218]. UV correction has yielded good results
with  those  drug  metabolites  that  share  the  same  chromophores,  and  thus  have  a
similar UV spectrum with the parent drug [223]. However, this approach should be
treated with caution as even with apparently similar UV spectra, quantification can
be erroneous if the chemical changes take place in the vicinity of a chromophore.
For example, the quantitative results for buspirone metabolites were enhanced by
UV correction, but a three-fold difference was nevertheless detected [222].
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NMR has traditionally been used as a reference technique for elucidating the
structures  of  drug  metabolites  in  the  pharmaceutical  industry.  The  emergence  of
Fourier transform NMR spectrometers along with improvements in both software
and hardware has increased the applicability of NMR also in quantitative analysis
[223,231].
The response of the universal detectors is fairly independent of the chemical
structure of the analyte, and hence these detectors may enable single-calibrant
quantification. CLND provides an equimolar response to nearly all nitrogen-
containing  compounds  and  has  been  successfully  applied  in  the  quantification  of
several drugs using caffeine for calibration [232-235]. In addition, LC-CLND
quantification of drugs in plasma and blood has been demonstrated when a
universal correction factor was used to compensate for the differences in extraction
recoveries [236,237]. The ELSD response depends on the mobile phase composition
of the LC gradient [238] but the differences in responses can be corrected with an
inverse LC gradient [239], while using chemically similar compounds for calibration
enables quantification without primary reference standards [240,241]. However,
CLND and ELSD are less sensitive than DAD for most drug analytes, making these
detectors less suitable for single-calibrant quantification of drugs in toxicological
samples [240,242].
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3. AIMS OF THE STUDY
The first aim of this thesis was to develop new analytical laboratory methods for the
analysis of toxic alcohols, medicinal drugs, and their metabolites in post-mortem
toxicology samples. The second aim was to gather metabolite concentration data by
these methods and apply the data to the interpretation of toxicological results.
The specific aims of the individual publications were
- To develop a qualitative screening method for volatile and semivolatile
compounds in blood samples by in-tube extraction-gas chromatography-
mass spectrometry (ITEX-GC-MS) (I)
- To develop a quantitative analysis method for ethylene glycol (EG),
glycolic  acid  (GA)  and  formic  acid  (FA)  in  blood  and  urine  samples  by
ITEX-GC-MS (I)
- To evaluate the concentrations of methanol (MeOH), EG and their acidic
metabolites in blood and urine samples from post-mortem cases (II, III)
- To develop a robust non-MS method based on ultra-high performance
liquid chromatography coupled with diode array detection and charged
aerosol detection (UHPLC-DAD-CAD) for quantitative monitoring of
toxicologically relevant basic drugs in blood samples (IV)
- To utilize UHPLC-DAD-CAD for quantitative monitoring of drug
metabolites without primary reference standards (V)
- To assess the meaning of combined parent drug – metabolite
concentrations and metabolite to parent ratios obtained by UHPLC-
DAD-CAD in post-mortem blood samples (V)
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4. MATERIALS AND METHODS
4.1 Materials
4.1.1 Chemicals and reagents
All reference standards for drugs were purchased from pharmaceutical companies
and were of pharmaceutical purity. Deuterated internal standards were purchased
from Aldrich (Steinheim, Germany), Isotec (Miamisburg, OH, USA), and Cambridge
Isotope Laboratories (Andover, MA, USA). All other chemicals were pro analysis,
liquid chromatography (LC), or LC-mass spectrometry (MS) grade and purchased
from various suppliers.
4.1.2 Post-mortem blood and urine samples
Post-mortem blood and urine samples were taken at medico-legal autopsies by
forensic pathologists for toxicological analysis and were stored refrigerated with a
preservative  (1%  sodium  fluoride)  prior  to  analysis.  Blood  samples  were  femoral
venous blood.
A  total  of  47  fatal  methanol  (MeOH)  or  ethylene  glycol  (EG)  poisonings  were
studied (II, III). Of these 23 were positive for MeOH, 21 were positive for EG and in
three cases both MeOH and EG were detected. The MeOH positive cases covered all
cases within a one-year period in which MeOH was found with headspace-gas
chromatography-flame ionization detection (headspace-GC-FID) in either blood or
urine samples or both (II). The EG positive cases represent a five-year period (III).
To  study  the  post-mortem  formation  of  formic  acid  (FA),  30  putrefied  cases were
analyzed along with 59 non-putrefied cases where no MeOH was detected. The
criterion for putrefaction was either a mention of decomposition in the covering
note from the forensic pathologist, or a long post-mortem interval and visual
inspection of the sample (II). To evaluate the usefulness of urinary oxalic acid (OX)
in screening for EG poisonings, 100 previously analyzed, non-EG positive urine
samples were re-analyzed for OX (III).   The selection of  cases for toxic alcohols is
presented in Fig. 4 (II, III).
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Figure 4. Selection of cases for analysis of toxic alcohols and their metabolites (II, III).
MeOH: methanol, FA: formic acid, EG: ethylene glycol, GA: glycolic acid, OX: oxalic acid.
To study the metabolite to parent ratios of therapeutic drugs, all previously
analyzed post-mortem blood samples within one year were examined. Samples
containing analytes of interest were retrospectively reprocessed with the secondary
calibration method utilizing the parent drug as calibration standard. From the
samples in which the parent and the metabolite concentrations exceeded the limit of
quantification (LOQ), the six most frequently occurring drugs were included in the
study (V).  The selection of  samples is  presented in Fig.  5.  Due to the frequency of
polydrug  use,  one  sample  could  contain  more  than  one  drug.   The  selected  cases
represented  all  causes  of  death  and  were  not  sorted  according  to  the  cause  or
manner of death or to any other attribute. The selected cases were divided into




Figure 5. Selection of cases for studying metabolite to parent ratios of medicinal drugs with
number of cases in parenthesis (V). LOQ: limit of quantification.
4.2 Sample preparation
4.2.1 Determination of formic acid, ethylene glycol, glycolic acid, and
volatile compounds
For the analysis of volatile organic compounds (VOC), the samples were diluted with
water and internal standard was added. For the determination of EG, glycolic acid
(GA), and FA, in-vial methylation with dimethylsulfate was performed for urine
samples and protein-precipitated blood samples (I-III).
4.2.2 Analysis of basic drugs and their metabolites
For the quantitative monitoring of basic drugs and their metabolites blood samples
were extracted under basic conditions with a mixture of ethyl acetate and butyl
acetate (IV, V). The organic layer was evaporated to dryness and reconstituted with
100 μL of 0.1% aqueous trifluoroacetic acid (TFA):MeOH (80:20, v:v). For
calibration and control samples, 50 μl of the standard or control mixture was added
to sheep whole blood prior to extraction.
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4.3 Instrumentation and analytical methods
4.3.1 ITEX-gas chromatography-mass spectrometry (ITEX-GC-MS)
GC-MS  was  performed  with  a  5975B  VL  mass  selective  detector  coupled  with  a
6890N gas chromatograph (Agilent Technologies, Santa Clara, CA, USA). The GC
was  equipped  with  a  CTC  CombiPal  autosampler  with  ITEX  (CTC  Analytics,
Zwingen,  Switzerland).  The column was a CP PoraPLOT Q HT capillary column of
25 m (and 2.5 m particle trap) x 0.32 mm i.d., with 10 μm film thickness (Varian,
Lake Forest, CA, USA). A 2.5 ml headspace syringe was used (Hamilton, Bonaduz,
Switzerland).  A Tenax TA (80/100mesh) trap was used in the syringe needle.  The
GC-MS was operated with ChemStation software with integrated CTC Control
software.
Analyte separation was performed with a thermal gradient from 40°C to 250°C
(15°C/min) with an initial isothermal period of 2 min. The isothermal period at the
end  was  4  min  for  the  determination  of  EG,  GA,  and  FA  and  10  min  for  the  VOC.
The mass detector was operated in electron ionization (EI) and full scan mode in the
range  m/z  15–550.  The  target  and  qualifier  ions  for  EG,  GA,  FA,  OX,  and  the
deuterated internal standards are presented in Table 2.
Table 2. Target and qualifier ions used for quantification of ethylene glycol, glycolic acid,
formic acid, oxalic acid, and deuterated internal standards by ITEX-GC-MS (I-III). ME:
methyl ester, 2ME: dimethyl ester
Derivative Target ion (m/z) Q1 (m/z) Q2 (m/z)
Ethylene-d4 glycol-2ME 94 64 47
Ethylene glycol-2ME 90 60 45
Glycolic-d2 acid-2ME 76 47
Glycolic acid-2ME 74 45
Oxalic acid-2ME 59 45 29
Formic-d acid-ME 61 32
Formic acid-ME 60 31
In both methods, the ITEX incubation time was 5 min, extraction volume 1500
μL, extraction speed 150 μL/min, needle temperature 55°C, desorption temperature
230°C, desorption speed 20 μL and injection volume 2000 μL. The incubation
temperature was 60°C for the VOC and 90°C for EG, GA, and FA. The number of




The chromatography instrumentation consisted of an Acquity UPLC® binary solvent
manager, sample manager and column manager (Waters Corporation, Milford, MA,
USA). Detection involved two consecutive detectors in series, the first being an
Acquity  PDA  detector  (Waters)  and  the  second  a  Corona  Ultra  CAD  (ESA
Biosciences, part of Thermo Scientific, Sunnyvale, CA, USA). Empower software
(Waters)  was  used  for  data  processing  (version  2  in IV and  version  3  in V),
chromatographic optimization was performed with Fusion AE (S-Matrix, Eureka,
CA, USA), and SPSS statistical software (SPSS Inc. Chicago, IL, USA) was used for
statistical analysis (version 20 in IV and version 23 in V).
UHPLC separation was performed with a HSS C18 column of 2.1 mm × 150 mm
equipped with a HSS C18 precolumn of 2.1 mm × 5.0 mm, both with a particle size
of 1.8 μm (Waters) using a mobile phase gradient consisting of 0.1% aqueous TFA
(mobile phase A) and MeOH (mobile phase B). The mobile phase was initially 5% B
(0–3 min), followed by a linear gradient from 5% B to 95% B (3–18 min) and held at
95% B (18–19 min).  To clean the column, a linear gradient from 95% B to 99% B
(19–19.5 min) followed and was held for 4 min. The equilibrium time between
samples  was  4  min.  The  flow  rate  was  0.4  mL/min  and  injection  volume  5  μl.
Column  temperature  was  60°C.  Ultraviolet  (UV)  spectra  were  collected  over  the
range 210–400 nm at collection speed of 20 point/sec and the quantification
wavelength was 230 nm. The CAD was operated using a nitrogen pressure of 35 psi.
The identification was based on retention time, UV spectrum, and the response
ratio  of  DAD  (230  nm)  to  CAD.  An  in-house  UV  library  was  created  for  the
wavelength range 210–400 nm with 1.2 nm resolution using standard solutions of
the drugs. Spectral matching was performed using Empower software by spectral
contrast angle (match angle). In this comparison method, spectra at the peak apex
are converted to vectors in n-dimensional space, the vectors are moved into a two-
dimensional  plane  and  the  angle  between  them  is  measured  using  linear  algebra.
The criterion for identification by UV spectrum was match angle ≤ 2.0°
(SI=0.9994). The detector response ratio was calculated by dividing analyte peak
area on the DAD by the corresponding peak area on the CAD. For each compound a
reference value was determined individually. The acceptance criterion for the
response ratio was set at ±30% tolerance from the reference value.
One-point calibration was performed with both detectors individually using
dibenzepin as internal standard. In the analysis of metabolite to parent ratios (V),
the historic calibrations of the parent drugs were used to quantify both the parent
drugs and the metabolites.
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5. RESULTS AND DISCUSSION
5.1 Hydroxylic and volatile compounds
5.1.1  Analytical laboratory methods
The headspace in-tube extraction gas chromatography-mass spectrometry (ITEX-
GC-MS) approach was developed for comprehensive analysis of low molecular
weight organic compounds in blood and urine. One aliquot was analyzed after in-
vial derivatization with dimethyl sulfate for ethylene glycol (EG), glycolic acid (GA),
formic acid (FA), and other hydroxylic compounds, and another aliquot for
underivatized volatile organic compounds (VOC).
In the case of FA, EG, and GA determinations by ITEX-GC-MS, derivatization is
needed to increase the volatility of these hydroxylic compounds. The basic methods
for derivatization of hydroxyl groups for GC analysis include acylation, alkylation,
esterification, and silylation [243]. Most derivatization agents require that the
analytes are extracted into an organic phase prior to derivatization. Dimethyl sulfate
has the distinct advantage that analytes can be transformed to the corresponding
methyl esters in aqueous matrices such as water and urine [244,245]. Previously, in
situ derivatization  with  dimethyl  sulfate  has  been  used  for  the  analysis  of  organic
acids and phenols in water [244-249] or urine samples [250] prior to GC-MS
analysis with headspace sampling [246], headspace-solid phase microextraction
(SPME) [245,247,250], or large-volume on-column injection [248].
The method for hydroxylic compounds enables the detection and identification
of many alcohols, glycols, phenolic compounds, and organic acids, including high
concentrations of γ-hydroxybutyric acid. Due to the decomposition of the dimethyl
sulfate reagent to methanol (MeOH) and sulfuric acid during the derivatization
process, simultaneous determination of MeOH was not possible with this method.
The  linear  concentration  ranges  obtained  for  FA,  GA,  and  EG  in  blood  and  urine
cover the toxicologically relevant range. The limits of detection (LOD) and
quantification  (LOQ)  for  EG  and  GA  are  similar  to  those  obtained  by  GC-flame
ionization detection (FID) or GC-MS using derivatization with phenylboronic acid
or silylation [251], but not as low as those obtained with direct injection into GC-MS
following derivatization with bis-N,O-trimethylsilyl trifluoroacetamide [147] or
isotope dilution GC-MS following derivatization with heptafluorobutyric anhydride
[148]. For FA, the LOD could not be determined in the present study because of the
endogenous FA found in all  post-mortem samples.  The LOQ of 0.05 g/L obtained
here is lower than that reported for GC-FID following derivatization with MeOH and
sulfuric acid [77,78].
The present screening method for volatile organic compounds allowed
identification of over 100 VOC, including lighter gas, gasoline additives, inhalation
anesthetics and miscellaneous solvents. Compared with previously published
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comprehensive screening methods [158,160], a wider range of VOC could be
identified in a single run. Compounds could even be tentatively identified without
primary reference standards based on their mass spectrum, and confirmed later
using the appropriate standard. The identification limits obtained for most VOC
were superior to those with static headspace techniques. The identification limits
were higher than those from purge and trap GC-MS [252], but comparable to those
of other methods used for screening volatile compounds in blood [81,253].
Choosing a porous open layer tubular (PLOT) column enabled the detection and
separation  of  very  volatile  gases  such  as  propane  and  butane  above  ambient
temperature. The chromatographic peak shape was generally good, but could be
improved for early eluting, very volatile compounds by using cryofocusing.
However,  as  a  result  of  the  poor  peak  shape,  the  limits  of  identification  for  lower
alcohols without derivatization were fairly high, and consequently ethanol and
MeOH are better determined using standard headspace GC techniques.
Quantification of VOC was tested with a single internal standard, diethyl ketone.
This enabled semiquantitative analysis, but for precise quantitative results
individual internal standards should be used. However, quantification of volatile
compounds  is  futile  [254],  as  their  concentration  in  the  blood  sample  can  be
diminished both before sampling and after sampling if  the sample container is  not
full or is opened and closed before the analysis.
5.1.2 Concentrations of toxic alcohols and their metabolites in post-
mortem samples
The mean and median concentrations and concentration ranges of MeOH, FA, EG,
and GA in fatal MeOH or EG poisoning cases are presented in Table 3. There was a
large variability in the urine concentrations of all the compounds, as well as in the
blood concentrations of MeOH and EG. However, there was a significant correlation
between the blood and urine concentrations of MeOH and EG, the Pearson
correlations being r2=0.928 for MeOH and r2=0.896 for EG. This is consistent with
previous studies of ethanol and MeOH [77,255]. The correlation between the blood
and urine concentrations of  both FA and GA was poor.  Even though FA is  a minor
metabolite of EG, in the present material elevated FA concentrations were not seen
in EG poisoning cases, which is consistent with a previous study with monkeys [31].
In all cases, the urine concentrations of MeOH, EG, FA, and GA were higher than
those in blood. This warrants the use of urine for screening purposes, whenever this
sample is available. In clinical settings, screening of FA and GA in blood or serum
samples  along  with  MeOH  and  EG  is  recommendable  if  the  patient  is  acidotic  or
suffers from oliguria or anuria.
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Table 3. Mean and median concentrations and concentration ranges of methanol (MeOH),
formic acid (FA), ethylene glycol (EG), and glycolic acid (GA) in fatal poisoning cases (II, III).
Compound Blood Urine
Mean Median Range Mean Median Range
MeOH 3.0 ‰ 3.0 ‰ 1.1–6.0 ‰ 4.4 ‰ 4.7 ‰ 1.6–8.7 ‰
FA 0.80 g/L 0.88 g/L 0.19–1.0 g/L 3.4 g/L 3.3 g/L 1.7–5.6 g/L
EG 1.5 g/L 0.87 g/L < LOQ–5.6 g/L 5.7 g/L 4.3 g/L 1.6–18 g/L
GA 1.6 g/L 1.6 g/L 0.69–2.3 g/L 5.2 g/L 5.4 g/L 2.6–8.3 g/L
Fig. 6 shows the blood FA and GA concentrations in fatal toxic alcohol poisoning
cases plotted against the concentration of MeOH and EG. As can be seen from Fig.
6,  there  is  no  correlation  between  the  concentration  of  the  parent  alcohol  and  the
acidic metabolite. Rather, the concentrations of FA and GA in blood samples seem
to be very uniform, suggesting that there is a fatal threshold for the metabolite
concentration in blood in nonhospitalized toxic alcohol ingestion cases. For FA this
concentration is approximately 0.8–1.0 g/L and for GA approximately 1.6–2.0 g/L.
These findings are consistent with previous studies of fatal MeOH and EG
poisonings [77,79], but previous authors have not discovered the fatal threshold
blood concentrations in their material. The fatal threshold concentrations are
roughly twice the clinical blood concentration associated with poor outcome, as the
admittance concentration of FA > 0.5 g/L has been shown to cause permanent
visual damage or death [76,77] and a GA concentration of 0.8 g/L to cause renal
injuries [28,71,256].
Other toxicologically relevant findings in the fatal MeOH or EG poisonings were
scarce. Ethanol was detected in only two urine samples and in one blood sample. As
ethanol has the highest affinity for alcohol dehydrogenase (ADH), it is metabolized
before  MeOH  and  EG.  Therefore,  it  is  difficult  to  estimate  the  role  of  ethanol  in
fatalities including toxic alcohols. The most common concomitant findings in the
fatal toxic alcohol poisoning cases were benzodiazepines. They were found in
therapeutic concentrations in one-third of the cases. Benzodiazepines are commonly
used  in  the  treatment  of  alcohol  abusers  [257]  and  as  part  of  intensive  care.   As
many of the fatal MeOH or EG poisoning victims had a history of alcohol abuse and
as  about  one-fourth  of  them  died  in  a  healthcare  unit,  this  result  is  reasonable.  In
two of the mixed MeOH/EG poisoning cases, the GA concentrations in both blood
and urine were very low or not detected at all, whereas the MeOH and FA
concentrations  were  high.  This  suggests  that  MeOH  was  consumed  prior  to,  or
simultaneously  with,  EG,  as  MeOH  has  a  higher  affinity  for  ADH  than  EG.  In  the
third case, MeOH and FA concentrations were substantially lower and GA was
present along with EG. In this case, EG was presumably ingested prior to MeOH.
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Figure 6. Distribution of FA and GA concentrations in blood in fatal MeOH and EG
poisoning cases.
Calcium oxalate monohydrate (COM) crystals are one of the factors contributing
to EG toxicity, and the crystals are detected in the kidneys in the majority of fatal EG
poisonings cases [79]. Of the EG poisoning cases studied in the present thesis, one
presented considerable EG and GA concentrations in blood and urine, but no visible
COM crystals were found in the kidneys. This suggests that death had occurred
before  formation  of  COM  crystals  due  to  the  toxicity  of  EG  and  GA,  as  their
concentrations were among the highest detected in the study. However, the lack of
COM crystals can complicate the cause of death investigation, as EG and GA are not
routinely screened in many forensic laboratories, and quantification of EG is often
performed only after COM crystals have been detected.
The urinary oxalic acid (OX) concentration was found to provide very little
additional information for the post-mortem diagnosis of EG poisoning. Even though
OX was not detected or the concentration was <0.10 g/L in 79% of the EG-negative
urine samples, there were individual cases in which the urinary OX concentrations
were even higher than those detected in the EG poisoning cases. This is probably
due to OX from dietary and endogenous sources [35].
The mean (median) concentration of FA in non-putrefied, non-MeOH positive
cases  was  0.04  g/L  (0.04  g/L)  in  blood  and  0.06  g/L  (0.04  g/L)  in  urine,  never
exceeding 0.2 g/L in blood or 0.3 g/L in urine. These results are consistent with the
previous studies of endogenous FA [32-34,258,259]. In putrefied samples, the FA
concentrations were significantly higher: the mean (median) FA concentration being
0.24  g/L  (0.22  g/L)  in  blood  and  0.25  g/L  (0.15  g/L)  in  urine.  The  FA
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concentrations ranged from below LOD to 0.77 g/L in blood and from 0.02 to 1.4
g/L in urine. In three cases the blood FA concentration exceeded 0.5 g/L, a level
suggesting fatal MeOH poisoning. In the re-analysis of ten putrefied blood and urine
samples, the FA concentrations were within ± 25% of the original results, which
suggests that the formation of FA took place before sampling, not during storage. A
probable  explanation  for  these  high  FA  concentrations  is  bacterial  breakdown  of
lipids, carbohydrates and proteins [88]. It has been demonstrated that FA
concentration can increase substantially in urine samples stored at room
temperature  due  to  bacteria  [258].  FA  has  also  been  found  in  decomposing  pig
carcasses  [91].  Even  though  post-mortem  production  of  EG  has  been  reported
[260], in this study no EG or GA was detected in post-mortem cases that were not
connected to EG ingestion.
A large proportion of deaths caused by toxic alcohols took place in a healthcare
unit. As many of the deceased had a history of ethanol abuse and as breath alcohol
analyzers may falsely interpret MeOH as ethanol [56], there is a chance of
misdiagnosis. Diagnosing intoxication caused by toxic alcohols rather than ethanol
still remains a difficult task, as the symptoms of the intoxication are similar to those
caused by ethanol. Furthermore, hospital laboratories seldom have appropriate
analytical tools to detect MeOH or EG, let alone their toxic metabolites. In Ireland,
only  2.6%  of  hospital  laboratories  had  assays  for  determining  MeOH  or  EG  [261].
The situation is similar in Finland, as only the biggest hospital laboratories have GC
methods for toxic alcohols. In a clinical setting, detecting the parent alcohols or
classic MeOH or EG poisoning symptoms may be sufficient to initiate treatment, but
quantification of the acidic metabolites aids the interpretation of the case in post-
mortem toxicology.
5.2 Medicinal drugs and their metabolites
5.2.1 Quantitative monitoring of basic drugs
A quantitative drug screening method for blood samples was developed based on
ultra-high performance liquid chromatography (UHPLC) with two consecutive
detectors:  diode  array  detector  (DAD)  and  charged  aerosol  detector  (CAD).
Chromatography was based on sub-2 μm C18 bonded phase sorbent and the mobile
phase consisted of 0.1% trifluoroacetic acid (TFA)/MeOH in gradient mode.
Identification of analytes was based on the precise retention time, ultraviolet (UV)
spectra,  and  the  response  ratio  of  DAD  to  CAD.  Calibration  was  based  on  historic
one-point calibration. The response ratio was introduced to enhance the
identification power of the method. Fig. 7 shows an example of the calculation of the
DAD  to  CAD  response  ratio,  and  Fig.  8  presents  the  response  ratios  of  154  drugs
across the retention time axis. As can be seen from Fig. 8, there is great divergence
between the response ratios even with closely eluting compounds. With the criteria
used for analyte identification, there was only one pair of drugs, citalopram and
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norcitalopram, that were undistinguishable. However, these compounds are
generally detected together and can be distinguished by their elution order.
Furthermore, the response ratios were repeatable over two orders of magnitude with
a  median  relative  standard  deviation  of  12%.  Based  on  these  results,  a  stricter
criterion for the response ratio could be applied in order to increase the reliability of
the identification. Analysis of 20 negative blood samples gave no false positive
results for basic drugs. The stability of retention times over a one-month period was
excellent and comparable to that obtained with GC using retention time locking
[262],  as  the  median  intermediate  precision  was  0.04%  and  the  median  absolute
difference in retention time was 0.01 min. The high precision was largely due to the
favorable chromatography of basic drugs as TFA ion-pairs [263].  In liquid
chromatography-MS (LC-MS) methods similar chromatographic precision has been
reported mostly in intra-assay experiments [264].
Figure 7. Example of diode array detector (DAD) to corona charged aerosol detector (CAD)
response ratio (RR) calculation for Compound 1 and Compound 2 in a calibration sample:
peak area from DAD is divided by peak area from CAD. Response ratio is compound-
dependent because the response of DAD is dependent on the UV spectrum and the
response of CAD is independent of structure.
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The linear range of the method was generally 0.05–5 mg/L, the lowest point
equalling the LOQ. In two previous studies, the response of CAD has been reported
to be non-linear over a wide concentration range [198,199], but in the present study
the calibration curves were linear over two orders of magnitude (r2 > 0.99). Similar
linearity has been reported in previous studies in which a corresponding
concentration range was used [201,265]. The LOQ was within the therapeutic range
for most compounds, but drugs with a low therapeutic concentration, such as some
antipsychotics, some adrenergic beta-blocking drugs, cannabinoids, and
buprenorphine, cannot be detected at their therapeutic or recreational
concentrations.
Figure 8. Distribution of diode array detector (DAD) to corona charged aerosol detector
(CAD) response ratios plotted against UHPLC retention time for 154 drug analytes.
The long-term stability of historic one-point calibration was found to be
appropriate for the purpose of quantitative monitoring. After one month, the
median bias from the initial result was 6.8%, and for most compounds the bias was
< 10%. For some compounds, however, more frequent calibration is needed because
of the limited stability of calibration. The results of a proficiency testing blood
sample containing codeine, tramadol, citalopram, methadone, and amitriptyline
were very good (z-score ≤ 1) when the quantification was performed with historic
one-point calibration. The method has been accredited by the Finnish Accreditation
Service FINAS.
Small-scale liquid-liquid extraction was selected for sample preparation because
of its broad scope and simplicity of operation. Several solvents, including
dichloromethane, ethyl acetate, butyl acetate and their mixtures were tested.
Extraction with dichloromethane, as suggested earlier [173], yielded good recoveries
but turned out to be impractical in routine analysis. A mixture of ethyl acetate and
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butyl  acetate  suggested  earlier  [266]  also  yielded  good  results,  but  a  mixture  of
50:50 generated non-soluble particles when the residue was reconstituted with the
injection solvent, and the proportion of ethyl acetate was therefore reduced to 25%
to avoid column blocking. The 20% MeOH content in the injection solvent was
necessary  to  dissolve  the  residue,  including  the  lipophilic  drugs,  prior  to
chromatography.
To ensure high throughput and reliable identification, the analytes were divided
up into five distinct data processing methods that were used concurrently. This
enabled reliable identification of close eluting compounds by presenting a maximum
of five drug candidates for each chromatographic peak based on the retention time.
The correct finding was then manually selected among the drug candidates based on
the UV spectrum and the DAD to CAD response ratio.
5.2.2 Quantification of drug metabolites employing parent calibration
Quantification of drug metabolites involving the use of a secondary calibration with
the parent drug generally yielded an accuracy comparable to ordinary drug
bioanalysis. The differences between primary and secondary calibration with each
detector for the 23 metabolites tested are presented in Fig. 9. The N-dealkylated
metabolites eluted in close proximity to their corresponding parent drugs and, in
addition, their UV spectra were very similar to those of the parent drugs. This
enabled the use of secondary calibration with the parent drug, the average difference
between primary and secondary calibration being 12% and 15% for CAD and DAD,
respectively. The quantitative results obtained with secondary calibration were
comparable to those obtained with LC-MS methods utilizing nanospray ionization
(NSI) [224]. However, unlike with LC-NSI-MS methods, no specialized
instrumentation was required for this level of accuracy in quantification. For the
O-demethylated metabolites the accuracy was poorer, due to differences in retention
time and UV spectra between parent drug and metabolite. The CAD results for
O-demethylated metabolites could be improved by using an inverse mobile phase




Figure 9. Relative differences in metabolite quantification between primary and secondary
calibration by UHPLC-DAD-CAD in post-mortem blood. Cetirizine is a metabolite of
hydroxyzine.
5.2.3 Metabolite to parent ratios of medicinal drugs in post-mortem
blood samples
The UHPLC-DAD-CAD data from 633 previously analyzed post-mortem blood
samples representing all causes of death was retrospectively reprocessed using the
secondary calibration method (V). The concentrations of six toxicologically relevant
drugs, amitriptyline, citalopram, mirtazapine, olanzapine, tramadol, and
venlafaxine, were ranked according to the combined parent drug-metabolite
concentration.  From  previous  studies  it  could  be  assumed  that  approximately  10–
20% of the cases were fatal poisonings caused by the drugs studied [108]. Three of
the drugs included in this study, amitriptyline, tramadol and venlafaxine, are among
the 20 most common drugs causing fatal poisonings in Finland [2]. Only those cases
for which both the parent drug and the metabolite concentration were above LOQ
were included in the study. Fig. 10 shows the distribution of the metabolite to parent
ratios in the three quartile groups of combined parent-metabolite concentration.
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Figure 10. Distribution of metabolite to parent drug concentration ratios in quartile groups of
combined parent-metabolite concentration in post-mortem blood.
In nearly 60% of these cases the concentration of the parent drug was above the
clinical therapeutic range in plasma, and in 27% of the cases the concentration was
at least twice as high as the median concentration for post-mortem cases reported
previously [108]. The median combined parent drug-metabolite concentrations
were 29–80% higher than the median parent drug concentrations, the average being
46%. The metabolite to parent ratios fell within the normal ranges defined in clinical
therapeutic drug monitoring (TDM) [9], even when the parent drug concentration
exceeded the therapeutic range. Only with the highest combined concentrations
were the ratios below the normal ranges. In the latter cases, the parent
concentrations were generally significantly above the clinical therapeutic range and
higher than the median post-mortem concentrations, suggesting acute overdose.
Furthermore, the present results are in agreement with the metabolite to parent
ratios of antidepressants measured in fatal poisoning cases and in other post-
mortem samples [16].
Fig. 11 illustrates the distribution of the metabolite to parent drug concentration
ratios in post-mortem blood positive for amitriptyline and venlafaxine. For each
drug,  the  horizontal  lines  correspond  to  the  upper  and  lower  limits  of  the  normal
clinical ratio defined for TDM [9], and the vertical line represents the post-mortem
median concentration according to a large database [108]. Fig. 11 shows that even
with fairly high amitriptyline concentrations, the metabolite to parent ratio falls
within the normal range, whereas in the case of venlafaxine, the ratio is already
below the normal range with moderate venlafaxine concentrations. One possible
explanation is the difference in post-mortem redistribution (PMR) behavior
between amitriptyline and venlafaxine. Amitriptyline has been reported to exhibit
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considerable  PMR  [267],  whereas  venlafaxine  has  been  found  to  be  less  prone  to
PMR with therapeutic concentrations in post-mortem samples close to those
defined in TDM [100,268]. It has been shown that in acute venlafaxine poisoning
cases the O-desmethylvenlafaxine to venlafaxine ratio is significantly lower,
approximately 0.1, than in other post-mortem cases, where the ratio is between 1
and 4 [16,268]. Hence, slightly elevated venlafaxine concentrations along with
significant concentrations of O-desmethylvenlafaxine are more likely to indicate
therapeutic use of venlafaxine than overdose [268].
Figure 11. Distribution of metabolite to parent ratios in amitriptyline and venlafaxine positive
cases. Horizontal lines correspond to normal ratio [9] and vertical lines represents post-
mortem median concentration of amitriptyline and venlafaxine [108].
These observations encourage the use of the metabolite to parent ratios in the
interpretation of toxicological results in cause of death investigations. Ratios outside
the normal ranges can indicate altered metabolism due to drug-drug interactions,
altered liver function, or genetic variation in the liver CYP enzymes, especially
CYP2D6 or CYP2C19. Low ratios and high combined concentrations can indicate
acute ingestion or poisoning. However, more data on metabolite concentrations and
metabolite to parent ratios in post-mortem blood should be acquired and connected
with cause of death information. Furthermore, drawing conclusions from these
results  is  complicated  by  the  high  pharmacological  activity  of  the O-demethylated




In toxicological analyses, there is a constant need to identify and quantify a wide
range  of  drugs  in  complex  biological  samples  [10],  and  the  use  of  two
complementary  sample  matrices  is  recommended  [183,269].  For  a  long  time,  gas
chromatography-mass  spectrometry  (GC-MS)  has  been  the  gold  standard  for
comprehensive drug screening, and several applications have been recently
presented [270-273]. GC-MS has good sensitivity and specificity and, thanks to the
high repeatability of electron ionization (EI), large mass spectral libraries are
available. However, only thermally stable and sufficiently volatile drugs can be
detected in their native form, others requiring derivatization [174,175]. Following
the emergence of ultra-high performance liquid chromatography (UHPLC) and a
range of advanced liquid chromatography (LC)-MS techniques, GC based methods
are today mostly used for volatile and semivolatile compounds.
Hydroxylic compounds and volatile organic compounds (VOC) represent an
important  and  diverse  group  of  toxicologically  relevant  substances,  but  the
prevalence of fatal poisoning cases by individual substances is low. In Finland,
methanol (MeOH) and ethylene glycol (EG) accounted for 1.7% of fatal poisonings
during 2011–2013, while the figure for VOC was 0.39% [2]. Consequently, utilizing
the same instrumentation enables a cost-effective way to analyze samples for all
these substances. The in-tube extraction (ITEX)-GC-MS method presented here is
the first that enables quantification of EG and glycolic acid (GA) along with other
compounds by headspace sampling instead of direct injection. The commonly used
direct injection technique is much more vulnerable to matrix effects and the
resulting false positive or negative findings. Using the two variants of the ITEX-GC-
MS method in parallel, i.e. derivatized and non-derivatized, permits comprehensive
screening of volatile and semivolatile compounds, including hydroxylic compounds.
In  addition,  the  porous  open  layer  tubular  (PLOT)  column  used  provides  high
chromatographic retention for very volatile compounds such as nitrous oxide and
hydrogen cyanide, allowing the determination of these compounds with only
minimal alterations to the current method [274,275]. In view of the high prevalence
of the recreational use of nitrous oxide by inhalation [276], associated with possible
accidental fatalities caused by asphyxiation, screening for this compound has
become more important.
The toxicity of MeOH and EG is mainly caused by their acidic metabolites,
formic acid (FA) and glycolic acid (GA), respectively, and there is a clear correlation
between the concentration of the acidic metabolite and the severity of the symptoms
[71,72,277]. No such correlation has been detected between the concentration of the
unchanged  alcohol  and  the  symptoms  [278].  The  present  results  concerning  fatal
MeOH and EG poisonings clearly support this understanding. Interestingly, in
nonhospitalized MeOH and EG poisoning cases, there seems to be a fatal threshold
concentration of FA and GA in blood. This result emphasizes the importance of
screening the acidic metabolites along with the parent alcohols in cases where
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ingestion of MeOH or EG is suspected. In post-mortem toxicology, the metabolite
concentration can verify that death was caused by ingestion of toxic alcohol.
In  a  clinical  context,  the  screening  of  MeOH  and  EG  usually  covers  only  the
unchanged alcohols, and these concentrations along with clinical symptoms are
used as the criteria for hemodialysis  [48,68,279].  Furthermore,  because of  the low
prevalence of poisonings caused by toxic alcohols, analytical methods even for
MeOH  and  EG  are  not  available  in  all  healthcare  units  [261].  There  are  recently
published chromatographic methods also covering the acidic metabolites that are
suitable for emergency toxicology [6,7].  A bedside test  for FA has also been made
available [73]. These improved diagnostic tools will obviously aid the recognition of
intoxications caused by toxic alcohols and reduce the number of fatal poisonings
caused by misdiagnosis or delayed treatment.
Another way to reduce fatalities caused by toxic alcohols is to limit their
availability. After Finland joined the European Union in 1995, MeOH-based
products  appeared  on  the  market.  This  led  to  an  enormous  increase  in  MeOH
poisonings, with 20–30 fatal cases each year [280]. In 2011, the availability of
products containing MeOH and EG was restricted by a government decree. Since
2011, the number of fatal MeOH and EG poisonings has decreased [2] but the long-
term effect of the new decree remains to be seen.
The majority of deaths associated with VOC are caused by direct toxicity of the
compounds concerned [84], and with the most commonly abused substances, such
as butane, cardiac arrest occurs soon after inhalation [83,281]. Analysis of VOC
metabolites is less relevant in post-mortem toxicology as the presence of the parent
compound in blood is  usually sufficient to prove the substance use [81].  However,
the  half-life  of  many  VOC  is  very  short,  and  detection  of  their  metabolites  could
extend  the  window  of  detection  in  suspected  VOC  abuse  cases  [86].  For  example,
the  half-life  of  alkyl  nitrates  is  only  a  few  minutes  [282]  and  the  toxicity  of  these
compounds is mainly caused by methemoglobinemia. Following metabolic
transformation, alkyl nitrates can be easily detected as the corresponding alcohols,
such as isopentyl alcohol [283]. In cases like this, the ability to detect and identify
both parent compound and metabolites can aid interpretation of toxicological
results. VOC metabolites may also help in assessment of the post-mortem interval
(PMI) [284-286]. Estimation of the time of death still remains one of the biggest
challenges in forensic medicine [287], and several recent studies have focused on
the  usefulness  of  metabolomics  in  post-mortem  biochemistry  [285-287].  Many  of
the compounds identified in the metabolic studies concerning biochemical changes
after death can be determined with the methods presented in (I), including glyoxylic
acid and oxalic acid (OX). Using ITEX-GC-MS in the selected ion monitoring (SIM)
mode  instead  of  full  scan  mode  would  increase  the  sensitivity,  and  selection  of
appropriate internal standards would enable quantification of these metabolites.
However, more research is still needed to evaluate the value of metabolites in PMI
investigations.
LC-MS enables the analysis of a broad range of toxicologically relevant
substances without derivatization [288]. LC-MS methods have become increasingly
important in recent years [12,13], and several screening methods are available [289-
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296]. These methods are fast, sensitive and selective, and the advances in accurate
mass measurement have enabled tentative identification of compounds even
without reference standards [297]. However, quantification by LC-MS with
electrospray ionization (LC-ESI-MS) is prone to matrix effects. To ensure reliable
quantitative results, matrix effects should be carefully studied during method
validation, and calibration needs to be performed frequently [221,298-300].
Furthermore, due to the inter-instrument variation in ionization, use of spectral
libraries in LC-MS is more limited than in GC-MS [301,302].
Before LC-MS methods became dominant in toxicological screening, high
performance liquid chromatography-diode array detection (HPLC-DAD) was a
standard technique for large-scale drug screening, and several methods are available
[173,178,303]. Compared to MS methods, LC-DAD is inexpensive, adequately
selective, and requires little instrument maintenance [177]. In addition, the long-
term stability of LC-DAD methods enables utilization of historic calibration [175].
LC-DAD still has a strong position in quantification, especially in the
pharmaceutical industry, but also in toxicological laboratories [304,305]. LC-MS,
GC-MS and LC-DAD techniques should be considered complementary to each other,
as none of these techniques is sufficient to detect and quantify all toxicologically
relevant compounds in a rational manner [304]. MS-based methods are invaluable
in the quantification of substances that have low therapeutic concentrations in blood
to ensure their appropriate detection [185]. MS-based techniques are also
indispensable in the identification and structural elucidation of unknown
compounds [305]
As DAD is not a destructive detector, it can be connected in series with another
detector, such as a corona charged aerosol detector (CAD) to gain more information
and enhance sensitivity for compounds with poor ultraviolet (UV) absorption. Using
the response ratio of DAD to CAD as an identification parameter is a novel approach
to increase the reliability of identification. Because of the variable UV response and
constant CAD response, the response ratios between basic drugs possess the desired
variation.
Assessing whether a drug concentration measured in a post-mortem blood
sample  is  on  the  fatal  level is complicated by post-mortem changes, mainly post-
mortem redistribution (PMR) [98-100,306]. For several drugs, the post-mortem
concentrations are significantly increased due to PMR, and as a general principle
drugs with volume of distribution (Vd) >3-4 L/kg have been considered to be more
prone to PMR. However, it has been demonstrated that the metabolite to parent
ratios may not be affected by PMR, as the concentrations of the metabolites of
amitriptyline, citalopram and fluoxetine, for example, increased in the same
proportion as the parent drug concentration [15,267,307]. However, this cannot be
generalized to all drugs. For example, the concentrations of amiodarone (Vd 66
L/kg)  do  not  change  due  to  PMR,  but  the  concentration  of  its  active  metabolite,
desmethylamiodarone, increases up to three-fold. Furthermore, the interpretation
of post-mortem concentrations is complicated by tolerance. For example with




The metabolite to parent ratio of tricyclic antidepressants has been used to
estimate the time of ingestion [15,309]. A very low ratio can be associated with acute
intoxication, while ratios within the normal range may be attributed to therapeutic
use.  This  assumption  was  further  supported  by  a  large  study  of  concentrations  of
antidepressants in post-mortem blood samples [16], showing that in fatal poisoning
cases, the ratios were lower than in cases where the cause of death did not relate to
poisoning. Furthermore, these ratios are comparable to those used in clinical
therapeutic  drug  monitoring  (TDM)  [9].  However,  more  data  on  the  metabolite
concentrations and metabolite to parent ratios in post-mortem samples is still
needed.
Quantification of metabolites in post-mortem samples is also important in
finding cases where altered metabolism may have caused adverse effects. For
example clobazam, an anticolvunsant often used with pediatric patients, has caused
several poisonings via its active metabolite norclobazam [116,310]. Both clobazam
and norclobazam are metabolized through CYP2C19, a polymorphic enzyme.
However, the half-life of norclobazam is much longer than that of clobazam, and in
poor metabolizers this causes accumulation of norclobazam at therapeutic doses.
Other drugs associated with altered concentrations of the active metabolite due to





In general, methods used for the determination of methanol (MeOH) and ethylene
glycol  (EG)  only  detect  the  parent  alcohol  in  blood  or  urine  samples.  However,
quantification of the acidic metabolites formic acid (FA) and glycolic acid (GA) is
necessary  for  the  diagnosis  of  toxic  alcohol  ingestion  and  for  cause  of  death
determination. The novel in-tube extraction-gas chromatography-mass
spectrometry (ITEX-GC-MS) method enabled facile quantification of EG, GA, and
FA following derivatization in biological samples. The parallel method was feasible
in the qualitative screening of volatile organic compounds (VOC), including fuel
gases, gasoline, alcohols, solvents, glues, anesthetic agents, and organic nitrites.
Using full-scan MS data acquisition allows detection of practically any low
molecular weight organic compound that is sufficiently volatile or can be volatilized
by methylation with the method developed here.
The ITEX-GC-MS method was used to study the concentrations of FA, EG, and
GA in fatal  poisoning cases due to toxic alcohols (II, III). The study revealed that
although  the  concentrations  of  MeOH  and  EG  in  blood  samples  are  largely
unpredictable,  the  fatal  concentrations  of  FA  and  GA  seem  to  settle  above  a
threshold value. For FA, the threshold value is 0.8–1.0 g/L and for GA 1.6–2.0 g/L.
These concentrations are approximately twice as high as those associated with poor
outcome  in  the  medical  treatment  of  poisoning.  It  was  shown  that  FA  is  formed
during putrefaction, presumably due to bacterial action and the decomposition of
lipids, carbohydrates and proteins (II). Thus, post-mortem FA concentration alone
cannot be used to reveal MeOH poisonings. It was also shown that the urinary oxalic
acid (OX) concentration does not provide much additional information in suspected
EG intoxication cases as the concentrations found are low and cannot be
distinguished from non-poisoning cases (III).
In post-mortem toxicology, both comprehensive screening methods and accurate
quantification methods are needed. GC-MS and liquid chromatography (LC)-MS
techniques can be used to quantify volatile and low-dose compounds, respectively,
but they require extensive calibration with primary reference standards to produce
reliable quantitative results. The ultra-high performance liquid chromatography-
diode array detection-corona charged aerosol detection (UHPLC-DAD-CAD)
method developed is a non-MS technique that enables quantitative monitoring of
161  basic  drugs  in  a  single  run  (IV).  The  method  provides  excellent  linearity  and
stability  based  on  historic  one-point  calibration  on  a  monthly  basis,  reducing  the
calibration workload compared to methods based on LC-MS. Furthermore, UHPLC-
DAD-CAD shows no ionization-related matrix effects associated with LC-MS
methods with electrospray ionization (ESI). The DAD to CAD response ratio
increases the reliability of identification compared to traditional DAD methods.
The UHPLC-DAD-CAD method enables the quantification of N-dealkylated drug
metabolites without primary reference standards by employing secondary
calibration with the parent drug (V). Limited reference data is available for
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metabolite concentrations in post-mortem toxicology, and consequently the method
developed can be used to accumulate this data on a routine basis. It is anticipated
that the combined parent drug – metabolite concentrations and the metabolite to
parent ratios, when connected to cause of death information and anamnesis, will
provide a more useful reference for the interpretation of toxicological results than
the concentration of the parent drug alone. Utilizing the metabolite concentrations
and the metabolite to parent ratios in interpretation of toxicological results requires
close co-operation between the forensic pathologist and the forensic toxicologist to
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